Your browser doesn't support javascript.
loading
How long should we continue clomiphene citrate in anovulatory women?
Weiss, N S; Braam, S; König, T E; Hendriks, M L; Hamilton, C J; Smeenk, J M J; Koks, C A M; Kaaijk, E M; Hompes, P G A; Lambalk, C B; van der Veen, F; Mol, B W J; van Wely, M.
Afiliación
  • Weiss NS; Center for Reproductive Medicine, Academic Medical Center, 1105 AZ Amsterdam, the Netherlands Center for Reproductive Medicine, Free University Medical Center, 1081 HZ Amsterdam, the Netherlands Department of Obstetrics and Gynaecology, Onze Lieve Vrouwe Gasthuis, 1091 AC Amsterdam, the Netherlands.
  • Braam S; Center for Reproductive Medicine, Academic Medical Center, 1105 AZ Amsterdam, the Netherlands Center for Reproductive Medicine, Jeroen Bosch Hospital, 5223 GZ Den Bosch, the Netherlands.
  • König TE; Center for Reproductive Medicine, Free University Medical Center, 1081 HZ Amsterdam, the Netherlands.
  • Hendriks ML; Center for Reproductive Medicine, Free University Medical Center, 1081 HZ Amsterdam, the Netherlands.
  • Hamilton CJ; Center for Reproductive Medicine, Jeroen Bosch Hospital, 5223 GZ Den Bosch, the Netherlands.
  • Smeenk JM; Department of Obstetrics and Gynaecology, St Elisabeth Hospital, 5000 LC Tilburg, the Netherlands.
  • Koks CA; Department of Obstetrics and Gynaecology, Máxima Medical Center, 5504 DB Veldhoven, the Netherlands.
  • Kaaijk EM; Department of Obstetrics and Gynaecology, Onze Lieve Vrouwe Gasthuis, 1091 AC Amsterdam, the Netherlands.
  • Hompes PG; Center for Reproductive Medicine, Free University Medical Center, 1081 HZ Amsterdam, the Netherlands.
  • Lambalk CB; Center for Reproductive Medicine, Free University Medical Center, 1081 HZ Amsterdam, the Netherlands.
  • van der Veen F; Center for Reproductive Medicine, Academic Medical Center, 1105 AZ Amsterdam, the Netherlands.
  • Mol BW; Center for Reproductive Medicine, Academic Medical Center, 1105 AZ Amsterdam, the Netherlands.
  • van Wely M; Center for Reproductive Medicine, Academic Medical Center, 1105 AZ Amsterdam, the Netherlands m.vanwely@amc.uva.nl.
Hum Reprod ; 29(11): 2482-6, 2014 Nov.
Article en En | MEDLINE | ID: mdl-25164024
ABSTRACT
STUDY QUESTION What is the effectiveness of continued treatment with clomiphene citrate (CC) in women with World Health Organization (WHO) type II anovulation who have had at least six ovulatory cycles with CC but did not conceive? SUMMARY ANSWER When women continued CC after six treatment cycles, the cumulative incidence rate of the ongoing pregnancy rate was 54% (95% CI 37-78%) for cycles 7-12. WHAT IS KNOWN ALREADY If women with WHO type II anovulation fail to conceive with CC within six ovulatory cycles, guidelines advise switching to gonadotrophins, which have a high risk of multiple gestation and are expensive. It is however not clear what success rate could be achieved by continued treatment with CC. STUDY DESIGN, SIZE, DURATION We performed a retrospective cohort study of women with WHO II anovulation who visited the fertility clinics of five hospitals in the Netherlands between 1994 and 2010. We included women treated with CC who had had at least six ovulatory cycles without successful conception (n = 114) after which CC was continued using dosages varying from 50 to 150 mg per day for 5 days. PARTICIPANTS/MATERIALS, SETTING,

METHODS:

Follow-up was a total of 12 treatment cycles. Primary outcome was the cumulative incidence rate of an ongoing pregnancy at the end of treatment. MAIN RESULTS AND THE ROLE OF CHANCE We recruited 114 women that had ovulated on CC for at least six cycles but had not conceived. Of these 114 women, 35 (31%) had an ongoing pregnancy resulting in a cumulative incidence rate of an ongoing pregnancy of 54% after 7-12 treatment cycles with CC. LIMITATIONS, REASONS FOR CAUTION Limitations of our study are its retrospective approach. WIDER IMPLICATIONS OF THE

FINDINGS:

Randomized trials comparing continued treatment with CC with the relatively established second line treatment with gonadotrophins are justified. In the meantime, we suggest to only begin this less convenient and more expensive treatment for women who do not conceive after 12 ovulatory cycles with CC. STUDY FUNDING/COMPETING INTERESTS None. TRIAL REGISTRATION NUMBER Not applicable.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inducción de la Ovulación / Clomifeno / Fármacos para la Fertilidad Femenina Tipo de estudio: Guideline / Observational_studies Límite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Hum Reprod Asunto de la revista: MEDICINA REPRODUTIVA Año: 2014 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inducción de la Ovulación / Clomifeno / Fármacos para la Fertilidad Femenina Tipo de estudio: Guideline / Observational_studies Límite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Hum Reprod Asunto de la revista: MEDICINA REPRODUTIVA Año: 2014 Tipo del documento: Article País de afiliación: Países Bajos